In this review, we will discuss the pathophysiologic anomalies of the tumor microenvironment in <i>TP53</i>-mutant MDS/AML, the hypothesized mechanisms of chemoresistance it imparts, and how novel therapies are leveraging diverse therapeutic targets to address this critical area of need. The gene discussed is TP53; the disease is acute myeloid leukemia.